364 related articles for article (PubMed ID: 22692814)
1. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
[TBL] [Abstract][Full Text] [Related]
2. Reducing selection bias in case-control studies from rare disease registries.
Cole JA; Taylor JS; Hangartner TN; Weinreb NJ; Mistry PK; Khan A
Orphanet J Rare Dis; 2011 Sep; 6():61. PubMed ID: 21910867
[TBL] [Abstract][Full Text] [Related]
3. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
[TBL] [Abstract][Full Text] [Related]
4. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
Basiri M; Ghaffari ME; Ruan J; Murugesan V; Kleytman N; Belinsky G; Akhavan A; Lischuk A; Guo L; Klinger K; Mistry PK
Elife; 2023 May; 12():. PubMed ID: 37249220
[TBL] [Abstract][Full Text] [Related]
6. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
7. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry.
Rosenbloom B; Balwani M; Bronstein JM; Kolodny E; Sathe S; Gwosdow AR; Taylor JS; Cole JA; Zimran A; Weinreb NJ
Blood Cells Mol Dis; 2011 Jan; 46(1):95-102. PubMed ID: 21067946
[TBL] [Abstract][Full Text] [Related]
8. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review.
Tauchmanovà L; De Rosa G; Serio B; Fazioli F; Mainolfi C; Lombardi G; Colao A; Salvatore M; Rotoli B; Selleri C
Cancer; 2003 May; 97(10):2453-61. PubMed ID: 12733144
[TBL] [Abstract][Full Text] [Related]
9. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
10. Bone and body composition of children and adolescents with repeated forearm fractures.
Goulding A; Grant AM; Williams SM
J Bone Miner Res; 2005 Dec; 20(12):2090-6. PubMed ID: 16294262
[TBL] [Abstract][Full Text] [Related]
11. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.
Magal I; Lebel E; Altarescu G; Itzchaki M; Rudensky B; Foldes AJ; Zimran A; Elstein D
Br J Haematol; 2006 Apr; 133(1):93-7. PubMed ID: 16512834
[TBL] [Abstract][Full Text] [Related]
13. Life expectancy in Gaucher disease type 1.
Weinreb NJ; Deegan P; Kacena KA; Mistry P; Pastores GM; Velentgas P; vom Dahl S
Am J Hematol; 2008 Dec; 83(12):896-900. PubMed ID: 18980271
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Bone Mineral Density by Dual-Energy X-Ray Absorptiometry and Bone Strength by Speed-of-Sound Ultrasonography in Adults With Gaucher Disease.
Baskin E; Dinur T; Lebel E; Tiomkin M; Elstein D; Zimran A
J Clin Densitom; 2016 Oct; 19(4):465-470. PubMed ID: 26781431
[TBL] [Abstract][Full Text] [Related]
15. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
16. Potential biomarkers of osteonecrosis in Gaucher disease.
Pavlova EV; Deegan PB; Tindall J; McFarlane I; Mehta A; Hughes D; Wraith JE; Cox TM
Blood Cells Mol Dis; 2011 Jan; 46(1):27-33. PubMed ID: 21075651
[TBL] [Abstract][Full Text] [Related]
17. Self-reported fractures and associated factors in women with systemic lupus erythematosus.
Lee C; Almagor O; Dunlop DD; Manzi S; Spies S; Ramsey-Goldman R
J Rheumatol; 2007 Oct; 34(10):2018-23. PubMed ID: 17787041
[TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Sevittz H; Laher F; Varughese ST; Nel M; McMaster A; Jacobson BF
S Afr Med J; 2022 Feb; 112(1):13518. PubMed ID: 35140000
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation.
McAvoy S; Baker KS; Mulrooney D; Blaes A; Arora M; Burns LJ; Majhail NS
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1231-6. PubMed ID: 20302963
[TBL] [Abstract][Full Text] [Related]
20. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
